Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of ZX008 in Dravet syndrome
NL-OMON49270Phase 3Active, not recruiting
- Sponsor
- Syneos Health
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fenfluramine in Dravet syndrome and epilepsy, sponsored by Syneos Health. Primary endpoint: Frequency of convulsive seizures. Started Jun 2017; status: active, not recruiting.
02
Drugs
fenfluramine
03
Conditions
Dravet syndromeepilepsy
Beyond the preview
Go deeper on NL-OMON49270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49270.